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A public health approach for deciding policy on infant
feeding and mother–infant contact in the context of
COVID-19
Nigel Rollins, Nicole Minckas, Fyezah Jehan, Rakesh Lodha, Daniel Raiten, Claire Thorne, Philippe Van de Perre, Mija Ververs, Neff Walker,
Rajiv Bahl, Cesar G Victora, on behalf of the WHO COVID-19 Maternal, Newborn, Child and Adolescent Health Research Network, Newborn and
Infant Feeding Working Groups

The COVID-19 pandemic has raised concern about the possibility and effects of mother–infant transmission of
SARS-CoV-2 through breastfeeding and close contact. The insufficient available evidence has resulted in differing
recommendations by health professional associations and national health authorities. We present an approach for
deciding public health policy on infant feeding and mother–infant contact in the context of COVID-19, or for future
emerging viruses, that balances the risks that are associated with viral infection against child survival, lifelong health,
and development, and also maternal health. Using the Lives Saved Tool, we used available data to show how different
public health approaches might affect infant mortality. Based on existing evidence, including population and survival
estimates, the number of infant deaths in low-income and middle-income countries due to COVID-19 (2020–21)
might range between 1800 and 2800. By contrast, if mothers with confirmed SARS-CoV-2 infection are recommended
to separate from their newborn babies and avoid or stop breastfeeding, additional deaths among infants would range
between 188 000 and 273 000.

Introduction
Exclusive and continued breastfeeding, skin-to-skin
contact initiated in the first hour of birth, and responsive
caregiving are strongly recommended by WHO for
all infants and young children. Kangaroo mother care is
also strongly recommended for all low-birthweight
newborn babies.1 High-quality evidence has shown
the benefits of these interventions on child survival,
health, and development. The COVID-19 pandemic,
caused by SARS-CoV-2 has, however, raised concern
about the possibility and effect of SARS-CoV-2
transmission through close contact between mothers
and their infants and breastfeeding. As of Aug 14, 2020,
analyses of breastmilk samples of 175 mothers with
confirmed SARS-CoV-2 infection have been reported,2
with SARS-CoV-2 RNA identified by RT-PCR in samples
from ten mothers. However, evidence of infectious virus
that is capable of replicating and infecting other cells3
and mother–infant transmission through breastmilk
has not been shown.
Interpretation of existing evidence and how it
should shape public health policy is challenging because
the population effects and long-term health outcomes
of COVID-19 among mothers and infants are
uncertain. WHO interim guidance4 (May 27, 2020), on
the basis of available evidence, recommends that
“mothers with suspected or confirmed COVID-19 should
be encouraged to initiate and continue breastfeeding”,
while implementing infection control measures, and
“should not be separated from their infants unless the
mother is too sick to care for her baby”. The guidance
notes that the severity of COVID-19 infections is
much lower in infants than in adults and that “COVID-19
in infants and children represents a much lower
risk to survival and health than the other infections
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and conditions that breastfeeding is protective against”.
Some national health agencies, however, have advised
separation of infants from mothers with suspected
or confirmed SARS-CoV-2 and avoidance of breast
feeding5,6—although some have revised their position. A
Cochrane review of 19 national policies reported no
consensus regarding whether breastfeeding should be
contraindicated among mothers with confirmed or
suspected COVID-19 and even among asymptomatic
mothers with unknown COVID-19 status.7 Reports of
SARS-CoV-2 RNA in breastmilk, even without evidence
of transmission, have fuelled uncertainty and anxiety
and even led some authors to recommend against
breastfeeding.8 Unsurprisingly, health workers and
communities are confused about appropriate infant
feeding recommendations.9 In some settings, local
policies to prevent COVID-19 have resulted in delays in
initiation of and disruption in breastfeeding among
mothers with unknown COVID-19 status.9 Furthermore,
the pandemic and related evidence gaps and anxieties are
egregiously being exploited as a marketing opportunity
by the breastmilk substitute industry.10,11

An approach for deciding public health policy
Even in the absence of high-quality data, public health
policy should, to the extent possible, be evidence-based.
We present an approach based on available evidence for
the competing benefits and harms (panel) for developing
policy on mother–infant contact and infant feeding
practices in the context of COVID-19, or for other viral
agents that might appear in the future, that balances
the risks associated with viral infection with the effect
on child survival, lifelong health, and development.
Considerations include the incidence among mothers,
duration of infectivity, feasibility of identifying infection
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Panel: Available evidence and key research and programme gaps

See Online for appendix

SARS-CoV-2 infection fatality rate
Available evidence
• Preliminary data from south Asia and Latin America indicate
very low infection fatality rates in infants and young children
(appendix p 7)
Research and programme gaps
• What is the infection fatality rate of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in
infants and young children by age, nutritional status,
comorbidity, socio-economic setting and health system
capacity?
Mortality and long-term health outcomes of mother–infant
contact and breastfeeding
Available evidence
• High quality data show survival and long-term health
benefits that are associated with early initiation of and
exclusive and continued breastfeeding (cumulative benefits
with longer durations of breastfeeding) and with mother–
infant contact (appendix p 7)
• Breastfeeding rates decrease when health-care workers
communicate mixed messages (appendix p 7)
• Breastfeeding rates decrease as a result of marketing of
breastmilk substitutes (appendix p 7)
Research and programme gaps
• What are the protective effects of specific anti-SARS-CoV-2
factors in breastmilk?
SARS-CoV-2 transmission risk through mother–infant
contact and breastfeeding
Available evidence
• SARS-CoV-2 RNA identified intermittently in breastmilk
• Evidence for transmission competent virus not reported in
breastmilk (appendix pp 7–8)
• No transmission through breastfeeding reported
• COVID-19 neonatal deaths mostly among preterm babies
and when the mother is seriously unwell (and therefore
separated; appendix pp 7–8)
• SARS-CoV-2 antibodies identified in breastmilk (appendix
pp 7–8)
• Lactoferrin and many other anti-infectious molecules
(eg, secretory leucocyte protease inhibitor and lysozymes)

in a timely manner, SARS-CoV-2 transmission risks, and
effects of infection in infants, alongside the mortality
and health risks of separation and not breastfeeding. In
time, relevant data will become available and should be
interpreted while recognising complementary effects of
these considerations and dependent outcomes. Here, we
consider the risk of exposure to SARS-CoV-2 that is
associated with close contact and breastfeeding and
compare this risk with the risks of no contact between
the mother and infant and avoidance or stopping of
breastfeeding (and use of breastmilk substitute).
e553

present in breastmilk with potential anti-SARS-CoV-2
activity (appendix pp 7–8)
Research and programme gaps
• Is active transmission-competent virus present in
breastmilk?
• If present, how frequently, for how long, and what is the
relationship to symptoms (before and after symptoms)?
• What is the transmission rate through respiratory droplets
and close contact by infant age and time in contact with
mother when asymptomatic or infectious?
• What is the additional transmission rate through breastfeeding
by infant age and amount of breastmilk consumed?
• What is the ability of virus to overcome host defences
according to infant age?
Identification of mothers with confirmed SARS-CoV-2
infection
Available evidence
• Testing done only once symptoms present or during a
contact tracing process (eg, when a relative or other
household member has symptoms or tests positive for
infection; appendix p 8)
• Some centres doing tests in all mothers who present in
labour (appendix p 8)
• Time to return of results 24–72 h or longer, although some
accredited tests provide PCR result within 60 min (GenXpert
and others; appendix p 8)
• Testing not available in many facilities, including
high-resource settings (appendix p 8)
• 5–20% of individuals with suspected COVID-19 are likely to
test positive for SARS-CoV-2;12 in other reports, 52–96% of
individuals who were tested because of symptoms
suggestive of COVID-19 were negative and had a different
cause of symptoms (appendix p 8)
Research and programme gaps
• What is the transmission risk associated with mother–infant
contact and other caregivers and household members while
the mother is asymptomatic or with early symptoms
(pre-results)?
• What are the best approaches for rapid testing?

Policy considerations for mothers with confirmed
SARS-CoV-2
On consideration of a balance of risk, public health
policy would favour separation and avoiding breast
feeding among mothers with confirmed SARS-CoV-2 if
evidence exists of substantial, immediate or potential
long-term adverse health effects of COVID-19 in infants
or young children; of substantive SARS-CoV-2 trans
mission through mother–infant contact or breastfeeding;
and identification of mothers with SARS-CoV-2 while
infectious, with or without symptoms. These conditions
www.thelancet.com/lancetgh Vol 9 April 2021
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are all necessary if avoidance of contact and breastfeeding
are to produce an overall benefit.
Conversely, public health policy for mothers with
confirmed SARS-CoV-2 infection would favour continued
breastfeeding and mother–infant contact if evidence
exists for substantial risk of immediate infant or child
death or long-term adverse effects associated with
separation and non-breastfeeding for the infant or
mother; few negative health effects of COVID-19 among
infants or young children; and low risk of SARS-CoV-2
transmission through mother–infant contact and
breastfeeding.
Mother–infant contact and breastfeeding are normative
recommendations and therefore standard of care. If any
of the inputs that justify separation and non-breastfeeding
are absent, then the chain of effects supporting a policy
that is different from standard care would be broken. For
mothers with suspected COVID-19 but who have not
been tested or confirmed, justification for a policy in
favour of separation and avoiding breastfeeding would
need evidence of a high likelihood of SARS-CoV-2
infection in those with suspected infection and even
greater harm associated with COVID-19 to allow for false
positives. A policy that is in favour of separation and nonbreastfeeding should also address the potential for
altered feeding practices in the general population—ie,
diminished breastfeeding because of public health mixed
messaging and confusion among health workers and
beliefs based on risk aversion.

COVID-19 chain of risks and effects of policy
options: illustrative analyses
Here, we consider the effects of inputs that sequentially
and cumulatively influence the balance of risks for
infants living in low-income and middle-income
countries (LMICs). We estimated the effects of separation
and non-breastfeeding by mothers with confirmed
SARS-CoV-2 (with or without symptoms), identified
either through universal testing of mothers of newborn
babies or through testing of mothers presenting with
COVID-19 symptoms. We estimated the potential
number of infant deaths in 119 LMICs (appendix pp 4–6)
that annually might be attributable to COVID-19 as well
as the additional deaths due to separation and nonbreastfeeding among infants who might be affected by
such a policy approach. We also present data that are
specific for 14 countries that show regional differences
in neonatal and child mortality. We assumed a SARSCoV-2 incidence rate among mothers of 10%, although
this figure is based on reported prevalence.13,14 In the
absence of reported incidence data, this figure therefore
overestimates actual incidence rates. SARS-CoV-2
transmission rates through close contact between a
mother who is infected but pre-symptomatic or
persistently asymptomatic and her infant are unknown.
A systematic review15 of 40 studies reported a mean
overall household secondary attack rate of 18·8%
www.thelancet.com/lancetgh Vol 9 April 2021

(95% CI 15·4–22·2; median 16·3% [IQR 10·5–24·0]).
Rates were higher from symptomatic than from
asymptomatic index cases, and lower to child contacts
than to adult contacts. The highest reported household
secondary attack rate was 44·6%.16 SARS-CoV-2 RNA
has been detected intermittently in breastmilk, but
replication-competent virus that is capable of infecting
other cells and presumably able to cause transmission
has not been reported.3 For these estimates, we examined
the effect of transmission probabilities of 20% and 30%.
SARS-CoV-2 infection fatality rates (IFRs) among infants
identified through universal screening of mothers are
also unknown. We, therefore, used case fatality rates
(CFRs) derived from infants and children who were
symptomatic for COVID-19, tested, and received medical
care. In a review of 7780 children in 26 countries with
confirmed COVID-19, the CFR was 0·09%.17 Using CFR
instead of IFR will therefore overestimate the number of
deaths potentially attributable to SARS-CoV-2 infection.
We used the Lives Saved Tool (LiST) and current
national mortality rates to estimate infant deaths in
2020–21 that were attributable to separation and nonbreastfeeding among approximately 104 000 000 livebirths
in 119 LMICs. LiST is a modelling tool for estimating
direct and indirect effects of changes in coverage of
health interventions, including skin-to-skin contact;
exclusive, partial, and predominant breastfeeding in
infants younger than 6 months; and any breastfeeding
from age 6 months to 23 months on infant and child
mortality (appendix pp 2–3).18 High-income countries
were not included. Breastfeeding prevalence rates in
LiST are based on country-specific data and are organised
by four age groups: 0–<1 month, 1–5 months,
6–11 months, and 12–24 months. The effect sizes of
breastfeeding on survival vary by time of initiation, age,
and category (ie, exclusive, predominant, or partial).19,20
We examined two scenarios among infants of mothers
with SARS-CoV-2 infection that was identified
immediately after birth—eg, in the context of universal
screening of mothers and also infants of mothers
identified through testing if symptomatic in the first
12 months after birth.
The first scenario was no initiation of breastfeeding
among exposed newborn babies and older infants
stopping breastfeeding, and no neonates or older
infants subsequently restarting breastfeeding after the
mother is no longer infectious—eg, if the mother
received no counselling or other support to help restart
breastfeeding. The second scenario involved early
initiation of breastfeeding among all newborn babies;
exposed newborn babies and older infants stopping
breastfeeding; 50% of neonates and older infants
restarting breastfeeding after mothers are no longer
infectious (eg, the mother receives good counselling
support and is able to restart breastfeeding); and
considering the effects of non-breastfeeding projected
through the first 12 months of life.

For more on LiST see
https://www.livessavedtool.org
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Infant mortality attributable to COVID-19 or a policy of
separation and non-breastfeeding among mothers with
confirmed SARS-CoV-2 infection
Based on existing evidence and the assumptions already
described, annual deaths potentially attributable to
COVID-19 in infants younger than 12 months in LMICs
would be approximately 1875 or 2809 globally depending
on whether the transmission probability is assumed to
be 20% or 30%. Estimated deaths in infants aged
0–12 months who might be affected by a policy of
separation and non-breastfeeding among mothers with
confirmed SARS-CoV-2 infection are presented in the
table. Deaths among infants affected by a policy of
separation and non-breastfeeding would be at least
67 times greater than mortality potentially attributable
to COVID-19 (table). Assuming 30% transmission,
one would need to avoid mother–infant contact and
breastfeeding among 3700 infants to prevent one COVID19-attributable death—ie, the number of newborn babies
and infants who might be exposed to a policy requiring
separation and non-breastfeeding in the event of maternal
SARS-CoV-2 infection divided by the number of
COVID-19 attributable deaths (table).

Discussion
Even assuming high rates of mother–infant SARS-CoV-2
transmission through contact and breastmilk and using
Livebirths

Neonatal
deaths
(per 1000
livebirths),
2018–19

COVID-19related
deaths in
infants*†‡

COVID-19related
deaths in
infants*‡§

Additional infant* deaths
because of early separation
and no breastfeeding
among exposed newborns
and infants
Scenario 1

Scenario 2

Ghana

864 720

23·95

16

23

1983

1311

Nigeria

7 197 225

36·02

130

194

49 518

35 117

South Africa

827

1 204 852

10·74

22

33

1300

Argentina

747 792

6·36

13

20

123

75

Guatemala

425 986

12·30

8

12

685

509
367

2 229 502

7·51

40

60

615

Lebanon

116 540

4·32

2

3

16

11

Pakistan

5 798 236

41·95

104

157

18 403

12 208

Mexico

Turkey

1 320 135

5·46

24

36

182

118

Indonesia

4 749 802

12·74

85

128

5809

4015

234 195

22·11

4

6

666

461

Papua New
Guinea
Thailand

709 759

5·02

13

19

95

62

23 724 430

22·73

427

641

46 937

31 928

Myanmar

942 842

36·74

17

25

2777

1926

Sri Lanka

326 879

4·49

6

9

49

34

104 051 261

17·67

1875

2809

273 453

188 626

India

All LMICs
(119 countries)

CFR=case fatality rate. LMIC=low-income and middle-income countries. Data are n. *Age 0–12 months. †Assuming
20% transmission rate and a CFR of 0·09%. ‡Assuming no separation and continued breastfeeding. §Assuming
30% transmission rate and a CFR of 0·09%.

Table: Estimated additional infant deaths (2020–21)

e555

CFR instead of IFR, the additional deaths among
newborn babies and infants in LMICs who would be
subjected to separation and non-breastfeeding in either
scenario (188 000 or 273 000) would be approximately
67 times greater than the number of newborn babies and
infants who are likely to die because of COVID-19.
Because we assume higher incidence, transmission, and
mortality associated with COVID-19 among newborn
babies and infants than has been reported to date, this
estimate is almost certainly an underestimate of the effect
on mortality of a policy that would separate mothers from
their newborn babies and disrupt breastfeeding. A low, or
even very low, CFR in SARS-CoV-2-infected infants and
children is the primary influence on this estimate,
although lower transmission risks among infants and
children, as suggested by existing evidence, are also
important. An observational study21 that included
116 mothers with confirmed SARS-CoV-2 reported no
transmission among their newborn babies aged up to
1 month, despite rooming in, and 78% practising breast
feeding. Mothers also practised simple precautionary
measures including wearing masks and hand hygiene.21
Although high-income countries are not included in
LiST, the benefits of exclusive and continued breastfeeding
and use of breastmilk—eg, for infants with necrotising
enterocolitis and for reducing hospital admissions for
infectious diseases—are also likely to greatly outweigh
the risks of COVID-19 in infants and young children. The
presence of SARS-CoV-2 RNA in breastmilk in the
absence of other evidence indicating that the virus can be
transmitted through breastmilk is an important
observation, but public health decisions that are based on
this finding alone are not justified.
The analyses only consider the immediate mortality
consequences of the two public health approaches. Yet,
the adverse effects of delays and interruptions of
breastfeeding might extend beyond any period of
transient cessation related to the risk for SARS-CoV-2
infection. Unless skilled breastfeeding counselling and
support is available to individual mothers to help
re-establish breastfeeding, temporary cessation is likely to
diminish rates and duration of continued breastfeeding.
Routine services have been disrupted by the pandemic in
most settings and coverage of breastfeeding counselling
is very likely to have also been affected.
Changes in feeding and care practice among mothers
who are only suspected to have COVID-19, or by mothers
of unknown status who are anxious or confused by the
lack of accurate health messaging or through opportunistic
marketing by the breastmilk substitute industry, will also
indirectly increase mortality and losses in health status. If
the non-survival benefits of breastfeeding for the child
and mother22 are also considered, then much higher
COVID-19 IFRs and transmission rates would be needed
to justify a policy of separation and non-breastfeeding.
Furthermore, separation of the infant from a mother with
confirmed or suspected COVID-19 does not necessarily
www.thelancet.com/lancetgh Vol 9 April 2021
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remove all transmission risks for the infant. Transmission
might also occur from exposure to infected but asympto
matic carers at home, in health facilities, or in the
community. In Brazilian national surveys, 13 (35%) of
37 family members of participants who tested positive for
SARS-CoV-2 antibodies also tested positive,23 inferring
that to effectively implement a policy of separation, infants
would have to be removed from their homes, which is
clearly unrealistic.
The absence of accurate risk data presents a challenge
for making public health recommendations. Empirical
data will, in time, inform where the thresholds between
low and high risks fall. While CFRs among infants and
children presenting to health facilities are becoming
available, IFRs, in which asymptomatic individuals and
cases of mild illness also contribute to the denominator,
are unknown and are perhaps not being investigated
in population surveys. Also, adverse outcomes in
young infants appear to have occurred principally among
neonates who were born preterm or whose mothers had
moderate-to-severe symptoms of COVID-19, making it
difficult to ascertain what is attributable to COVID-19
alone. In-utero transmission seems likely24 and might
also bias postnatal outcome data, further complicating
the interpretation of contact and infant feeding data
in neonates. The protective effects of breastmilk against
transmission of SARS-CoV-2 and the potential to mitigate
infection through specific antibodies and anti-infectious
agents in breastmilk are yet to be understood. However,
components of breastmilk such as IgA, lactoferrin, and
other anti-infectious molecules (eg, secretory leucocyte
protease inhibitor and lysozymes) are likely to provide
broad protection against viral invasion.
The COVID-19 pandemic shows how evidence with
respect to infant feeding and care practices can be
inconsistently assessed. The lack of consensus in
recommendations and public health messaging
suggests that risk aversion to the possible effects of
COVID-19 have outweighed consideration of the
survival and health benefits that skin-to-skin contact
and breastfeeding offer to newborn babies and young
infants. These mixed messages and concerns echo some
of the perspectives and disagreement that occurred
during the HIV epidemic when, in some settings,
avoidance of postnatal transmission was prioritised at
almost any cost. Yet the transmission risks and
consequences of COVID-19 are very different from
those of HIV.25 The COVID-19 pandemic shows how
approaches to policy making, whether in the context of
COVID-19 or other infectious diseases, need to consider
the full balance of risks, including the consequences of
interrupting evidence-based infant-feeding practices
and other standards of care.

Conclusions
On the basis of available evidence, including
programmatic information and illustrative analyses,
www.thelancet.com/lancetgh Vol 9 April 2021

we make five conclusions. First, the state of evidence and
balance of risk estimates support mother–infant close
contact and breastfeeding by mothers with confirmed
SARS-CoV-2 infection while still implementing infection
prevention and control measures, including hand
washing and wearing face masks.4 The survival benefits
of breastfeeding substantially outweigh the very low
reported CFRs among infants with COVID-19.4 Second,
public health authorities should consider the full
scope of evidence and implications for all-cause child
mortality and other health outcomes, and ensure that
resultant policy and associated messaging are coherently
communicated to health-care workers and communities.
Third, research will populate the evidence gaps and
future estimations should adopt a comprehensive child
survival and health framing to avoid oversimplification.
Animal models would be helpful for elucidating
infectivity of viruses through breastfeeding. Fourth, in
the COVID-19 pandemic, breastfeeding counselling and
support and other interventions and approaches should
focus on how to reduce the small risk of transmission
and effect through respiratory spread. Fifth, public health
authorities and legislators should proactively address the
deliberate exploitation and seeding of doubt about
breastfeeding by commercial interests.
Future epidemics caused by novel viruses will
probably involve similar challenges. The approach that
we have presented will be useful for planning concerted
advice that is globally consistent on risks and benefits
associated with breastfeeding in light of potential viral
transmission.
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